Press Releases Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Real-time Estimate Cboe BZX Other stock markets 12:16:55 2024-05-14 pm EDT			5-day change	1st Jan Change
0.644 ^USD	-0.25%		-4.88%	-15.34%

May. 07	Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	CI
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Traws Pharma : Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies	May. 07	PU
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	May. 07	GL
Traws Pharma Announces New Employee Inducement Grants	Apr. 02	AQ
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company	Apr. 02	AQ
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024	Mar. 08	AQ
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	Dec. 12	AQ
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's	Dec. 11	AQ
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s	Dec. 08	AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference	Nov. 29	AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference	Nov. 28	AQ
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results	Nov. 14	AQ
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023	Nov. 07	AQ
Poster Presentation Monday, Dec. 11th 6:00-8:00p PT	Nov. 02	PU
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL	Nov. 02	AQ
Onconova Expands Leadership Team with Two Key Appointments	23-10-24	AQ
Promising Preclinical Narazaciclib Data Presented at MCL Meeting	23-10-19	AQ
Encouraging Rigosertib Data Presented at EADV as Late Breaker	23-10-12	AQ
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress	23-09-28	AQ
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Press Releases

Filters